The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Inclusion Criteria:

1. Patients with advanced malignant tumor confirmed by histology or pathology, failedby standard treatment, no standard treatment or no standard treatment is applicable;

2. Eastern Cooperative Oncology Group (ECOG) 0 or 1;

3. Life expectancy ≥ 12 weeks;

4. At least one measurable lesion according to RECIST 1.1;

5. Adequate organ function;

Exclusion Criteria:

1. central nervous system metastasis；

2. There is a pleural, abdominal or pericardial effusion that is clinically symptomaticor requires repeated management (puncture or drainage, etc.)；

3. Images in screening showed that the tumor surrounded important blood vessels or hadobvious necrosis and voids, and the investigators believed that it might causebleeding risk；

4. The presence of severe, unhealed or open wounds, active ulcers, or untreatedfractures；

5. A history of significant bleeding tendency or severe coagulopathy；

6. The presence of poorly controlled hypertension；